

# Clinical and instrumental study on the anti-ageing effects of creams with hyaluronic acid, with and without Vitamin C

<b>Submission date</b> 25/07/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/07/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 28/07/2025	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aim

Skin ageing is a multifaceted process influenced by both intrinsic and extrinsic factors, resulting in visible changes such as wrinkles, loss of elasticity, uneven skin tone, and hyperpigmentation. Hyaluronic acid (HA) is widely recognized for its hydrating and structural support properties, while Vitamin C is known for its antioxidant and depigmenting effects. This study investigated the anti-ageing effect of two topical formulations containing Jalubalance® technology - HA delivered in Opuntia oil, with or without 1% Vitamin C.

### Who can participate?

Women aged between 30 and 50 years with mild to moderate photoaging

### What does the study involve?

Participants were assigned to apply either HA-only cream (Group A) or a HA + Vitamin C cream (Group B) twice daily. The primary outcome was the percentage of subjects who achieved an improvement of at least one point in the hyperpigmentation score from baseline to week 8. Additionally, the study aimed to evaluate and compare the effects of both treatments, with a particular focus on improvements in wrinkles, elasticity, hydration, and pigmentation.

### What are the possible benefits and risks of participating?

Benefits: improvement in skin ageing parameters. There are no expected risks for the participants.

### Where is the study run from?

Donne Dermatologhe Italia (Italy)

### When is the study starting and how long is it expected to run for?

February 2025 to June 2025

### Who is funding the study?

Cantabria Labs Difa Cooper (Italy)

Who is the main contact?  
Dr Massimo Milani, massimo.milani@difacooper.com

## Contact information

### Type(s)

Public, Scientific, Principal Investigator

### Contact name

Dr Stefano Alfano

### Contact details

Via Milano 160  
Caronno Pertusella  
Italy  
21042  
+39 (0)3802607820  
stefano.alfano@difacooper.com

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

Nil known

## Study information

### Scientific Title

Clinical and instrumental evaluation of the anti-ageing effectiveness of a cream based on hyaluronic acid and a cream based on hyaluronic acid and Vitamin C: a prospective, multicenter, 8-week, parallel-group randomized study on 91 subjects

### Study objectives

The addition of 1% Vitamin C in a face cream improves skin quality parameters

### Ethics approval required

Ethics approval not required

### Ethics approval(s)

### Study design

Prospective multicenter 8-week parallel-group randomized study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Medical and other records

### **Study type(s)**

Efficacy

### **Participant information sheet**

Not available in web format, please use the contact details to request a participant information sheet

### **Health condition(s) or problem(s) studied**

Skin aging

### **Interventions**

Patients were randomized in a 1:1 ratio and instructed to apply a cream formulated with red algae and Lactobacillus, enriched with Jalubalance® technology (high-concentration hyaluronic acid delivered through Opuntia oil) (HA-only cream, Group A), or to apply a cream that combines the Jalubalance® technology with 1% Vitamin C (HA-Vitamin C cream, Group B). The products were applied to the entire face twice daily (morning and evening) for 8 weeks, using 1.5 g of product per application (3 FTUs) on cleansed skin. A dedicated computer program was used to generate the randomization list.

### **Intervention Type**

Other

### **Primary outcome measure**

1. The percentage of subjects who achieved an improvement of at least one point in the hyperpigmentation score from baseline to week 8
2. Glogau score and a clinical score that assessed four parameters (wrinkles, elasticity, skin uniformity, and hyperpigmentation) with a 4-point score for each item (ranging from 0 = no issue to 3 = severe issue) from baseline to week 8

### **Secondary outcome measures**

1. Instrumental evaluation of treatment efficacy using the Digital Skin Moisture Meter, which measures skin hydration, sebum content, and skin elasticity, from baseline to week 8
2. VISIA® objective face sculptor analysis performed in a subgroup of 10 subjects from baseline to week 8

### **Overall study start date**

01/02/2025

### **Completion date**

01/06/2025

# Eligibility

## Key inclusion criteria

1. Women with mild to moderate photoaging (Glogau score 1 or 2)
2. Age between 30 and 50 years

## Participant type(s)

Healthy volunteer

## Age group

Adult

## Lower age limit

30 Years

## Upper age limit

50 Years

## Sex

Female

## Target number of participants

Group A: 47, Group B: 44

## Total final enrolment

91

## Key exclusion criteria

1. Pregnancy or breastfeeding
2. Allergy to components present in the products
3. Acute facial skin diseases

## Date of first enrolment

01/02/2025

## Date of final enrolment

01/04/2025

# Locations

## Countries of recruitment

Italy

## Study participating centre

Donne Dermatologhe Italia

Piazza Della Repubblica N 1/a

Milan

Italy  
20121

## Sponsor information

### Organisation

Cantabria Labs Difacooper

### Sponsor details

Via Milano 160  
Caronno Pertusella  
Italy  
21042  
+39 (0)3802607820  
stefano.alfano@difacooper.com

### Sponsor type

Industry

## Funder(s)

### Funder type

Industry

### Funder Name

Cantabria Labs Difa Cooper

## Results and Publications

### Publication and dissemination plan

Publication in a peer-reviewed journal

### Intention to publish date

06/05/2026

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the privacy of the patients involved

### IPD sharing plan summary

Not expected to be made available